These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 10595347)
1. Progress in antisense technology: the end of the beginning. Crooke ST Methods Enzymol; 2000; 313():3-45. PubMed ID: 10595347 [No Abstract] [Full Text] [Related]
2. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361 [No Abstract] [Full Text] [Related]
4. Design of antisense and triplex-forming oligonucleotides. François JC; Lacoste J; Lacroix L; Mergny JL Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350 [No Abstract] [Full Text] [Related]
5. Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides. Dheur S; Saison-Behmoaras TE Methods Enzymol; 2000; 313():56-73. PubMed ID: 10595349 [No Abstract] [Full Text] [Related]
6. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565 [TBL] [Abstract][Full Text] [Related]
7. In vitro transport and delivery of antisense oligonucleotides. Hughes J; Astriab A; Yoo H; Alahari S; Liang E; Sergueev D; Shaw BR; Juliano RL Methods Enzymol; 2000; 313():342-58. PubMed ID: 10595365 [TBL] [Abstract][Full Text] [Related]
8. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Stein CA Biochim Biophys Acta; 1999 Dec; 1489(1):45-52. PubMed ID: 10806996 [TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: preparation and in vivo application to rat brain. Tischmeyer W Methods Enzymol; 2000; 314():275-90. PubMed ID: 10565020 [No Abstract] [Full Text] [Related]
11. A cytosine analog that confers enhanced potency to antisense oligonucleotides. Flanagan WM; Wolf JJ; Olson P; Grant D; Lin KY; Wagner RW; Matteucci MD Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3513-8. PubMed ID: 10097067 [TBL] [Abstract][Full Text] [Related]
12. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Holmlund JT Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839 [TBL] [Abstract][Full Text] [Related]
13. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Temsamani J; Roskey A; Chaix C; Agrawal S Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906 [TBL] [Abstract][Full Text] [Related]
14. Crohn's trial shows the pros of antisense. Robertson D Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911 [No Abstract] [Full Text] [Related]